Atea Pharmaceuticals (AVIR) News Today $3.37 +0.04 (+1.20%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Atea Pharmaceuticals director Franklin Berger acquires $81,498 in stockJanuary 17 at 6:48 PM | msn.comShort Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Decreases By 12.9%Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) was the target of a significant decline in short interest in December. As of December 31st, there was short interest totalling 2,770,000 shares, a decline of 12.9% from the December 15th total of 3,180,000 shares. Currently, 3.7% of the shares of the stock are short sold. Based on an average daily volume of 309,000 shares, the short-interest ratio is currently 9.0 days.January 17 at 6:30 PM | marketbeat.comBarclays PLC Has $593,000 Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Barclays PLC grew its position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 74.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 177,077 shares of the company's stock after acquiring an additional 75,624January 17 at 3:10 AM | marketbeat.comAtea Pharmaceuticals to highlight 2025 strategic prioritiesJanuary 14, 2025 | markets.businessinsider.comAtea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 13, 2025 | finance.yahoo.comAtea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest UpdateAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 3,180,000 shares, a growth of 21.8% from the November 30th total of 2,610,000 shares. Currently, 4.3% of the shares of the stock are short sold. Based on an average daily volume of 266,600 shares, the days-to-cover ratio is presently 11.9 days.December 29, 2024 | marketbeat.comConcerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review ProcessDecember 18, 2024 | businesswire.comAtea Pharmaceuticals Retains Financial Advisor to Explore Strategic PartnershipsDecember 16, 2024 | globenewswire.comInsider Selling: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Director Sells 359,606 Shares of StockDecember 13, 2024 | insidertrades.comFmr LLC Buys 182,174 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Fmr LLC raised its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 2.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,618,297 shares of the company's stock after buying an additional 182,174 shareDecember 10, 2024 | marketbeat.comAtea Pharmaceuticals Hold Rating: Promising Phase 2 Outcomes Amidst Clinical and Market ChallengesDecember 6, 2024 | markets.businessinsider.comAfter Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C StudyDecember 4, 2024 | benzinga.comAtea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)December 4, 2024 | globenewswire.comAtea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx ConferenceNovember 26, 2024 | globenewswire.comAtea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024November 15, 2024 | globenewswire.comBML Capital Management LLC Has $22.28 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)BML Capital Management LLC increased its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 4.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,650,000 shares of the company's stock after pNovember 12, 2024 | marketbeat.comAtea Pharmaceuticals (AVIR) Gets a Hold from Morgan StanleyNovember 12, 2024 | markets.businessinsider.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comAtea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comAtea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comAtea Pharmaceuticals (AVIR) Scheduled to Post Quarterly Earnings on ThursdayAtea Pharmaceuticals (NASDAQ:AVIR) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comAtea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024October 30, 2024 | globenewswire.comDimensional Fund Advisors LP Buys 211,428 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Dimensional Fund Advisors LP boosted its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 55.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 594,360 shares of the compaOctober 12, 2024 | marketbeat.com182,326 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Purchased by Marshall Wace LLPMarshall Wace LLP purchased a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 182,326 shares of the company's stockOctober 10, 2024 | marketbeat.comAtea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ...October 9, 2024 | finance.yahoo.comAtea Pharmaceuticals (NASDAQ:AVIR) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comAlmitas Capital LLC Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Almitas Capital LLC acquired a new stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,290,187 shares of the company's stock, valued at approximately $4September 29, 2024 | marketbeat.comJean-Pierre Sommadossi Sells 33,941 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) StockSeptember 20, 2024 | insidertrades.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasted to Earn Q3 2024 Earnings of ($0.43) Per ShareAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Analysts at William Blair upped their Q3 2024 earnings per share (EPS) estimates for shares of Atea Pharmaceuticals in a research report issued to clients and investors on Monday, September 16th. William Blair analyst A. Hsieh now expects tSeptember 18, 2024 | marketbeat.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Sees Large Growth in Short InterestAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 2,830,000 shares, a growth of 13.7% from the August 15th total of 2,490,000 shares. Approximately 3.8% of the company's shares are short sold. Based on an average trading volume of 233,300 shares, the short-interest ratio is presently 12.1 days.September 15, 2024 | marketbeat.comAdobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market SessionSeptember 15, 2024 | msn.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19September 14, 2024 | finanznachrichten.deAtea Pharmaceuticals: Hold Rating Amidst Clinical Trial Setbacks and Future HepC FocusSeptember 14, 2024 | markets.businessinsider.comAtea Pharmaceuticals Shares Fall on Covid-19 Treatment Trial ResultSeptember 13, 2024 | marketwatch.comAtea Pharmaceuticals Trial of Covid-19 Treatment Bemnifosbuvir Fails to Meet Primary EndpointSeptember 13, 2024 | marketwatch.comAtea Pharma's Phase 3 SUNRISE-3 Study Of Bemnifosbuvir To Treat Covid-19 FailsSeptember 13, 2024 | markets.businessinsider.comAtea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' VirusSeptember 13, 2024 | finance.yahoo.comAtea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19September 13, 2024 | globenewswire.comAtea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation PathwayAugust 28, 2024 | finance.yahoo.comAtea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation PathwayAugust 28, 2024 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | insidermonkey.comAVIR Jan 2025 5.000 putAugust 14, 2024 | ca.finance.yahoo.comMorgan Stanley Upgrades Atea Pharmaceuticals (AVIR)August 14, 2024 | msn.comAVIR Jan 2025 7.500 callAugust 13, 2024 | ca.finance.yahoo.comAtea rises after Morgan Stanley upgradeAugust 13, 2024 | msn.comAtea Pharmaceuticals (NASDAQ:AVIR) Upgraded by Morgan Stanley to Equal WeightMorgan Stanley raised Atea Pharmaceuticals from an "underweight" rating to an "equal weight" rating and raised their price target for the stock from $2.00 to $6.88 in a report on Tuesday.August 13, 2024 | marketbeat.comNVO Aug 2024 75.000 putAugust 13, 2024 | ca.finance.yahoo.comNVO Aug 2024 110.000 callAugust 13, 2024 | ca.finance.yahoo.comNVO Aug 2024 170.000 callAugust 13, 2024 | ca.finance.yahoo.com Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address AVIR Media Mentions By Week AVIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVIR News Sentiment▼0.970.41▲Average Medical News Sentiment AVIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVIR Articles This Week▼61▲AVIR Articles Average Week Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Bicycle Therapeutics News Intellia Therapeutics News Rocket Pharmaceuticals News Zymeworks News Adaptive Biotechnologies News Gyre Therapeutics News Poseida Therapeutics News Oculis News Nuvation Bio News Anavex Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVIR) was last updated on 1/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVIR Stock Alerts